## NK cell-based immunotherapy for malignant diseases

Cellular and Molecular Immunology 10, 230-252 DOI: 10.1038/cmi.2013.10

**Citation Report** 

#	ARTICLE	IF	CITATIONS
1	Frontiers in natural killer cell immunology. Cellular and Molecular Immunology, 2013, 10, 185-186.	10.5	3
2	Human Induced Pluripotent Stem Cells from Basic Research to Potential Clinical Applications in Cancer. BioMed Research International, 2013, 2013, 1-11.	1.9	21
3	Antibody - Fc Receptor Interactions in Antimicrobial Functions. Current Immunology Reviews, 2013, 9, 44-55.	1.2	19
4	Immunotherapy for colorectal cancer. World Journal of Gastroenterology, 2013, 19, 8531.	3.3	76
5	An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget, 2014, 5, 10949-10958.	1.8	25
6	Tumor-released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape from NK Cell Attack. Journal of Biological Chemistry, 2014, 289, 33311-33319.	3.4	104
7	Natural Killer Cells for Cancer Immunotherapy: Pluripotent Stem Cells-Derived NK Cells as an Immunotherapeutic Perspective. Frontiers in Immunology, 2014, 5, 439.	4.8	78
8	Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy. International Journal of Molecular Sciences, 2014, 15, 20209-20239.	4.1	65
9	Cell Transfer Therapy for Cancer: Past, Present, and Future. Journal of Immunology Research, 2014, 2014, 1-9.	2.2	30
10	The Role of the Immune Response in Chlamydia trachomatis Infection of the Male Genital Tract: A Double-Edged Sword. Frontiers in Immunology, 2014, 5, 534.	4.8	80
11	Sweet escape: Sialic acids in tumor immune evasion. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 238-246.	7.4	94
12	STAT1-S727 - the license to kill. Oncolmmunology, 2014, 3, e955441.	4.6	9
13	A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy. Journal of Immunology Research, 2014, 2014, 1-16.	2.2	24
14	CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia, 2014, 28, 917-927.	7.2	370
15	NK Cell Trafficking in Health and Autoimmunity:A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2014, 47, 119-127.	6.5	24
16	Low-doses of sequential-kinetic-activated interferon-Î <sup>3</sup> enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study. International Immunopharmacology, 2014, 19, 66-73.	3.8	34
17	Natural killers take on cancer. Nature, 2014, 505, 483-483.	27.8	6
18	Cell-mediated delivery of nanoparticles: Taking advantage of circulatory cells to target nanoparticles. Journal of Controlled Release, 2014, 190, 531-541.	9.9	231

ATION RED

#	Article	IF	CITATIONS
19	Clinical utility of natural killer cells in cancer therapy and transplantation. Seminars in Immunology, 2014, 26, 161-172.	5.6	154
20	Recombinant soluble CD226 protein directly inhibits cancer cell proliferation in vitro. International Immunopharmacology, 2014, 19, 119-126.	3.8	10
21	Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. Cellular and Molecular Immunology, 2014, 11, 495-502.	10.5	90
22	Bispecific antibody platforms for cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2014, 92, 153-165.	4.4	78
23	Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer. Molecular Biology Reports, 2014, 41, 6317-6323.	2.3	4
24	Genital Chlamydia trachomatis: Understanding the Roles of Innate and Adaptive Immunity in Vaccine Research. Clinical Microbiology Reviews, 2014, 27, 346-370.	13.6	81
25	Antibody-dependent cellular cytotoxicity and cytokine/chemokine secretion by KHYG-1 cells stably expressing FcγRIIIA. Immunology Letters, 2014, 161, 59-64.	2.5	3
26	In Vivo Monitoring of Natural Killer Cell Trafficking during Tumor Immunotherapy. Magnetic Resonance Insights, 2014, 7, MRI.S13145.	2.5	19
27	HPV16E7 silencing enhances susceptibility of CaSki cells to natural killer cells. Molecular Medicine Reports, 2014, 9, 1351-1354.	2.4	1
28	Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood, 2014, 124, 3241-3249.	1.4	85
29	2015 Guidance on cancer immunotherapy development in earlyâ€phase clinical studies. Cancer Science, 2015, 106, 1761-1771.	3.9	16
30	Activated NKT cells imprint NK ell differentiation, functionality and education. European Journal of Immunology, 2015, 45, 1794-1807.	2.9	17
31	Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain. BMC Cancer, 2015, 15, 1011.	2.6	64
32	Adenanthin, a new inhibitor of thiolâ€dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. Immunology, 2015, 146, 173-183.	4.4	16
33	Natural Killer Cells Differentiate Human Adipose-Derived Stem Cells and Modulate Their Adipogenic Potential. Plastic and Reconstructive Surgery, 2015, 136, 503-510.	1.4	4
34	<scp>TNF</scp> â€i±: a treatment target or cause of sarcoidosis?. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2104-2111.	2.4	67
35	Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. International Journal of Nanomedicine, 2015, 10, 5981.	6.7	29
36	Alloferon Alleviates Dextran Sulfate Sodium-induced Colitis. Immune Network, 2015, 15, 135.	3.6	9

#	Article	IF	CITATIONS
37	Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century. Stem Cells International, 2015, 2015, 1-19.	2.5	127
38	The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Frontiers in Immunology, 2015, 6, 578.	4.8	220
39	Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack. International Journal of Molecular Sciences, 2015, 16, 30405-30421.	4.1	14
40	Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Frontiers in Immunology, 2015, 6, 230.	4.8	65
41	Natural Killer Cell Immunotherapy: From Bench to Bedside. Frontiers in Immunology, 2015, 6, 264.	4.8	29
42	Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells. PLoS ONE, 2015, 10, e0142767.	2.5	21
43	Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. Journal of Immunology Research, 2015, 2015, 1-14.	2.2	30
44	Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes. Scientifica, 2015, 2015, 1-8.	1.7	4
45	CD8+ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity. Critical Reviews in Immunology, 2015, 35, 153-172.	0.5	32
46	Modulation of inflammation by low and high doses of ionizing radiation: Implications for benign and malign diseases. Cancer Letters, 2015, 368, 230-237.	7.2	108
47	Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. Breast Cancer Research, 2015, 17, 70.	5.0	11
48	MICA SNPs and the NKG2D system in virus-induced HCC. Journal of Gastroenterology, 2015, 50, 261-272.	5.1	41
49	Innate Immune Recognition of Cancer. Annual Review of Immunology, 2015, 33, 445-474.	21.8	431
50	Ascorbic acid promotes proliferation of natural killer cell populations inÂculture systems applicable for natural killer cell therapy. Cytotherapy, 2015, 17, 613-620.	0.7	59
51	Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacologica Sinica, 2015, 36, 1191-1199.	6.1	144
52	Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation. Nanomedicine, 2015, 10, 1761-1774.	3.3	17
53	Haploidentical Haematopoietic Stem Cell Transplantation: Role of NK Cells and Effect of Cytomegalovirus Infections. Current Topics in Microbiology and Immunology, 2015, 395, 209-224.	1.1	13
54	Lack of in Vivo Antibody Dependent Cellular Cytotoxicity with Antibody Containing Gold Nanoparticles. Bioconjugate Chemistry, 2015, 26, 812-816.	3.6	23

#	Article	IF	CITATIONS
55	Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. Expert Opinion on Biological Therapy, 2015, 15, 857-872.	3.1	18
56	Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy, 2015, 17, 621-632.	0.7	74
57	Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Human Vaccines and Immunotherapeutics, 2015, 11, 851-869.	3.3	67
58	Genetically modified T cells in cancer therapy: opportunities and challenges. DMM Disease Models and Mechanisms, 2015, 8, 337-350.	2.4	137
59	Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells. Oncolmmunology, 2015, 4, e1036212.	4.6	64
60	Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6. Journal of Biological Chemistry, 2015, 290, 29964-29973.	3.4	64
61	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. Expert Opinion on Biological Therapy, 2015, 15, 1491-1500.	3.1	6
62	Agonist antibody that induces human malignant cells to kill one another. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6158-E6165.	7.1	16
63	Comprehensive assessment of cancer missense mutation clustering in protein structures. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5486-95.	7.1	195
64	Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980.	2.0	83
65	In Vivo Imaging of Natural Killer Cell Trafficking in Tumors. Journal of Nuclear Medicine, 2015, 56, 1575-1580.	5.0	37
66	Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies–A review. Oncolmmunology, 2015, 4, e1002720.	4.6	31
67	Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells. Cancer Letters, 2015, 368, 26-35.	7.2	15
68	Natural killer cells: The journey from puzzles in biology to treatment of cancer. Cancer Letters, 2015, 357, 454-467.	7.2	42
69	Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients. Cancer Immunology, Immunotherapy, 2015, 64, 201-211.	4.2	15
70	Genomic expression profiling of NK cells in health and disease. European Journal of Immunology, 2015, 45, 661-678.	2.9	13
71	NK cells regulating T cell responses: mechanisms and outcome. Trends in Immunology, 2015, 36, 49-58.	6.8	175
72	Synthetic immunology: modulating the human immune system. Trends in Biotechnology, 2015, 33, 65-79.	9.3	41

C		F		~ ~ ~
CH.	AHC	JN I	(EP)	<b>JKL</b>

#	Article	IF	CITATIONS
73	Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia, 2015, 29, 387-395.	7.2	51
74	CD8 T Cell–Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas. Cancers, 2016, 8, 71.	3.7	8
75	Immune Cells in Cancer Therapy and Drug Delivery. Mediators of Inflammation, 2016, 2016, 1-13.	3.0	26
76	Cytokines Induce Faster Membrane Diffusion of MHC Class I and the Ly49A Receptor in a Subpopulation of Natural Killer Cells. Frontiers in Immunology, 2016, 7, 16.	4.8	7
77	"Natural Regulatorsâ€: NK Cells as Modulators of T Cell Immunity. Frontiers in Immunology, 2016, 7, 235.	4.8	112
78	Cord Blood as a Source of Natural Killer Cells. Frontiers in Medicine, 2015, 2, 93.	2.6	56
79	The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression. Frontiers in Oncology, 2016, 6, 54.	2.8	46
80	Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. Antibodies, 2016, 5, 1.	2.5	34
81	Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0157830.	2.5	69
82	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy, 2016, 8, 907-921.	2.0	20
83	'Trained immunity: consequences for lymphoid malignancies. Haematologica, 2016, 101, 1460-1468.	3.5	21
84	Phenotypically distinct helper NK cells are required for gp96-mediated anti-tumor immunity. Scientific Reports, 2016, 6, 29889.	3.3	17
85	Analysis of tumor populations and immune system interaction model. AIP Conference Proceedings, 2016, , .	0.4	2
86	Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. Scientific Reports, 2016, 6, 21678.	3.3	43
87	Novel immunotherapies for the treatment of melanoma. Immunotherapy, 2016, 8, 613-632.	2.0	5
88	Comparison of postoperative immune function in patients with thoracic esophageal cancer after video-assisted thoracoscopic surgery or conventional open esophagectomy. International Journal of Surgery, 2016, 30, 155-160.	2.7	12
89	Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer. Methods in Molecular Biology, 2016, 1441, 277-284.	0.9	8
90	The influence of miR-34a expression on stemness and cytotoxic susceptibility of breast cancer stem cells. Cancer Biology and Therapy, 2016, 17, 614-624.	3.4	11

ARTICLE IF CITATIONS # Natural Killer Cells. Methods in Molecular Biology, 2016, , . 0.9 2 91 mRNA Transfection to Improve NK Cell Homing to Tumors. Methods in Molecular Biology, 2016, 1441, 231-240. Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study. Journal of 93 2.5 17 Cancer Research and Clinical Oncology, 2016, 142, 2561-2567. Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer 94 1.8 xenograft model. Oncology Letters, 2016, 12, 1868-1876. Recent Advances in Stem Cells. Pancreatic Islet Biology, 2016, , . 95 0.3 1 A blessing and a curse: is high NK cell activity good for health and bad for reproduction?. Human Fertility, 2016, 19, 166-172. 1.7 Highly efficient IL-21 and feeder cell-driven <i>ex vivo</i> expansion of human NK cells with 97 4.6 62 therapeutic activity in a xenograft mouse model of melanoma. Oncolmmunology, 2016, 5, e1219007. What rheumatologists need to know about innate lymphocytes. Nature Reviews Rheumatology, 2016, 8.0 12,658-668. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor 99 1.4 136 capacity of NK cells. Blood, 2016, 128, 1475-1489. Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activityin 4.6 vitroandin vivoagainst chronic lymphocytic leukemia. Oncolmmunology, 2016, 5, e1211220. Transient Tcf3 Gene Repression by TALE-Transcription Factor Targeting. Applied Biochemistry and 101 2.9 3 Biotechnology, 2016, 180, 1559-1573. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and 12.4 1,844 combinations. Science Translational Medicine, 2016, 8, 328rv4. Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T 103 3.3 17 cells. Scientific Reports, 2016, 6, 32470. Morphofunctional Characteristics of Human Lymphocytes after In Vitro Activation. Bulletin of Experimental Biology and Medicine, 2016, 161, 731-735. 104 0.8 Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of 105 43 5.5chemoresistant bladder cancer stem-like cells. BMC Medicine, 2016, 14, 163. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with 39 Multiple Myeloma. Clinical Cancer Research, 2016, 22, 5959-5965. Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nature Communications, 2016, 7, 107 12.8 86 11154. Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. , 2016, 4, 78.

#	Article	IF	CITATIONS
109	The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients. Oncology Letters, 2016, 12, 3191-3194.	1.8	5
110	B7H6â€derived peptides trigger TNFâ€Î±â€dependent immunostimulatory activity of lymphocytic NK92â€MI cells Biopolymers, 2016, 106, 658-672.	<sup>•</sup> 2.4	8
111	Mathematical model of tumor–immune surveillance. Journal of Theoretical Biology, 2016, 404, 312-330.	1.7	63
112	Diacylglycerol Kinase ζ Is a Target To Enhance NK Cell Function. Journal of Immunology, 2016, 197, 934-941.	0.8	39
113	Potentiating Immune System by Hyperthermia. , 2016, , 127-135.		3
114	Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cellular and Molecular Immunology, 2016, 13, 57-64.	10.5	31
115	Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients. Cancer Immunology, Immunotherapy, 2016, 65, 181-192.	4.2	27
116	A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Cancer Letters, 2016, 372, 166-178.	7.2	43
117	Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies. Cytotherapy, 2016, 18, 80-90.	0.7	31
118	Liver natural killer cells: subsets and roles in liver immunity. Cellular and Molecular Immunology, 2016, 13, 328-336.	10.5	150
119	Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. Oncolmmunology, 2016, 5, e1160184.	4.6	13
120	<sup>19</sup> F-MRI for monitoring human NK cells <i>in vivo</i> . Oncolmmunology, 2016, 5, e1143996.	4.6	48
121	Natural Killer Cells. Current Topics in Microbiology and Immunology, 2016, , .	1.1	5
122	Killer-cell immunoglobulin-like receptor genes and ligands and their role in hematologic malignancies. Cancer Immunology, Immunotherapy, 2016, 65, 427-440.	4.2	28
123	Chip-based platform for dynamic analysis of NK cell cytolysis mediated by a triplebody. Analyst, The, 2016, 141, 2284-2295.	3.5	7
124	Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer. Trends in Cell Biology, 2016, 26, 215-226.	7.9	71
125	Natural killer cell receptors: alterations and therapeutic targeting in malignancies. Immunologic Research, 2016, 64, 25-35.	2.9	36
126	Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells. Oncogene, 2016, 35, 2584-2591.	5.9	7

#	Article	IF	CITATIONS
127	Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunology, Immunotherapy, 2016, 65, 465-476.	4.2	34
128	Antitumor dendritic cell–based vaccines: lessons from 20Âyears of clinical trials and future perspectives. Translational Research, 2016, 168, 74-95.	5.0	116
129	Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. Journal of Leukocyte Biology, 2016, 99, 87-96.	3.3	73
130	Natural killer cell adoptive immunotherapy: Coming of age. Clinical Immunology, 2017, 177, 3-11.	3.2	40
131	Bench to bedside: NK cells and control of metastasis. Clinical Immunology, 2017, 177, 50-59.	3.2	71
132	Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. Journal of Surgical Research, 2017, 211, 30-38.	1.6	8
133	The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia. International Journal of Laboratory Hematology, 2017, 39, 129-136.	1.3	13
134	Structural effects of sulfated polysaccharides from Codium fragile on NK cell activation and cytotoxicity. International Journal of Biological Macromolecules, 2017, 98, 117-124.	7.5	51
135	Altered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells. Scientific Reports, 2017, 7, 41381.	3.3	7
136	KIR genes and HLA class I ligands in a Caucasian Brazilian population with colorectal cancer. Human Immunology, 2017, 78, 263-268.	2.4	11
137	Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress. Cancer Immunology, Immunotherapy, 2017, 66, 605-613.	4.2	26
138	Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. Scientific Reports, 2017, 7, 43873.	3.3	28
139	NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine. Cancer Immunology Research, 2017, 5, 211-221.	3.4	57
140	Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. Oncolmmunology, 2017, 6, e1303586.	4.6	17
141	Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer. Immunology Letters, 2017, 186, 20-27.	2.5	31
142	Donor selection for <i>ex vivo</i> expanded natural killer cells as adoptive cancer immunotherapy. Future Oncology, 2017, 13, 1043-1047.	2.4	12
143	Bitter Melon Enhances Natural Killer–Mediated Toxicity against Head and Neck Cancer Cells. Cancer Prevention Research, 2017, 10, 337-344.	1.5	74
144	Natural killer cells as a promising tool to tackle cancer—A review of sources, methodologies, and potentials. International Reviews of Immunology, 2017, 36, 220-232.	3.3	10

	Сіта	tion Report	
#	Article	IF	Citations
145	Natural killer cells in inflammatory heart disease. Clinical Immunology, 2017, 175, 26-33.	3.2	79
146	Hide-and-seek: the interplay between cancer stem cells and the immune system. Carcinogenesis, 2017, 3 107-118.	38, <u>2.8</u>	78
147	NK Cell–derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells. Journal of Immunotherapy, 2017, 40, 265-276.	2.4	86
148	Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunologic Research, 2017, 65, 880-887.	2.9	55
149	The frog skin host-defense peptide frenatin 2.1S enhances recruitment, activation and tumoricidal capacity of NK cells. Peptides, 2017, 93, 44-50.	2.4	8
150	Activated Natural Killer Cells Mediate the Suppressive Effect of Interleukin-4 on Tumor Development via STAT6 Activation in an Atopic Condition Melanoma Model. Neoplasia, 2017, 19, 537-548.	5.3	11
151	Emerging and investigational therapies for neuroblastoma. Expert Opinion on Orphan Drugs, 2017, 5, 355-368.	0.8	27
152	Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer. Cell Death and Disease, 2017, 8, e2740-e2740.	6.3	65
153	Immunotherapy for infectious diseases in haematological immunocompromise. British Journal of Haematology, 2017, 177, 348-356.	2.5	11
154	Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Cancer Letters, 2017, 398, 62-69.	7.2	34
155	Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer. Immunology Letters, 2017, 184, 98-104.	2.5	29
156	Targeting the ubiquitin-conjugating enzyme E2D4 for cancer drug discovery–a structure-based approach. Journal of Chemical Biology, 2017, 10, 51-67.	2.2	9
157	Mass Cytometry Analytical Approaches Reveal Cytokineâ€Induced Changes in Natural Killer Cells. Cytometry Part B - Clinical Cytometry, 2017, 92, 57-67.	1.5	40
158	Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition. Scientific Reports, 2017, 7, 7958.	3.3	43
159	Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer. Molecular Immunology, 2017, 92, 45-53.	2.2	29
160	NK cell recruitment and exercise: Potential immunotherapeutic role of shear stress and endothelial health. Medical Hypotheses, 2017, 109, 170-173.	1.5	9
161	Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers. Molecular Therapy, 2017, 25, 2607-2619.	8.2	72
162	Gut-liver axis: gut microbiota in shaping hepatic innate immunity. Science China Life Sciences, 2017, 60, 1191-1196.	4.9	21

		CITATION REF	PORT	
#	Article		IF	CITATIONS
163	NK cell-based immunotherapy for cancer. Seminars in Immunology, 2017, 31, 37-54.		5.6	246
164	Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on a non-small cell lung cancer. Immunology Letters, 2017, 191, 10-15.	stage IV	2.5	31
165	Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody. Scientific Reports, 2017, 7, 11075.		3.3	40
166	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in anti-tumor immunotherapy. Seminars in Immunology, 2017, 31, 64-75.	NK-mediated	5.6	110
167	Natural killer cells in HIV-1 infection and therapy. Aids, 2017, 31, 2317-2330.		2.2	90
168	Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promisir Journal of Cancer Research and Clinical Oncology, 2017, 143, 2607-2618.	g treatment.	2.5	43
169	Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colored Cellular Physiology and Biochemistry, 2017, 44, 1038-1050.	tal Cancer.	1.6	35
170	RSK2 phosphorylates T-bet to attenuate colon cancer metastasis and growth. Proceeding National Academy of Sciences of the United States of America, 2017, 114, 12791-12796	gs of the	7.1	17
171	Uncovering the underlying mechanism of cancer tumorigenesis and development under a microenvironment from global quantification of the landscape. Journal of the Royal Socie Interface, 2017, 14, 20170105.	an immune ty	3.4	28
172	High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Cancer Immunology, Immunotherapy, 2017, 6	6, 51-61.	4.2	28
173	Natural killer cell-mediated cytotoxicity is increased by a type II arabinogalactan from And formosanus. Carbohydrate Polymers, 2017, 155, 466-474.	vectochilus	10.2	11
174	Natural Killer Cells Promote Fetal Development through the Secretion of Growth-Promoti Factors. Immunity, 2017, 47, 1100-1113.e6.	ng	14.3	228
175	Hemacytotoxicity and natural killer lytic index: New parameters to evaluate natural killer immunity for clinical use in cancer. Oncology Letters, 2017, 15, 1325-1333.	cell	1.8	1
176	Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinic of recurrent breast cancer. OncoTargets and Therapy, 2017, Volume 10, 4273-4281.	al outcome	2.0	34
177	Expression Profiles of Ligands for Activating Natural Killer Cell Receptors on HIV Infected Uninfected CD4+ T Cells. Viruses, 2017, 9, 295.	and	3.3	17
178	STATs in NK-Cells: The Good, the Bad, and the Ugly. Frontiers in Immunology, 2016, 7, 69	4.	4.8	91
179	In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of M Colorectal Cancer. Frontiers in Immunology, 2017, 8, 87.	etastatic	4.8	43
180	FcÎ <sup>3</sup> Receptor Heterogeneity in Leukocyte Functional Responses. Frontiers in Immunolog	y, 2017, 8, 280.	4.8	99

#	Article	IF	CITATIONS
181	Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Frontiers in Immunology, 2017, 8, 625.	4.8	56
182	CD56 in the Immune System: More Than a Marker for Cytotoxicity?. Frontiers in Immunology, 2017, 8, 892.	4.8	239
183	Developmental and Functional Control of Natural Killer Cells by Cytokines. Frontiers in Immunology, 2017, 8, 930.	4.8	203
184	Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies. Frontiers in Immunology, 2017, 8, 1090.	4.8	40
185	"Multi-Omics―Analyses of the Development and Function of Natural Killer Cells. Frontiers in Immunology, 2017, 8, 1095.	4.8	20
186	Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor. Frontiers in Immunology, 2017, 8, 1212.	4.8	20
187	Antibody Engineering for Pursuing a Healthier Future. Frontiers in Microbiology, 2017, 8, 495.	3.5	111
188	Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 1797.	4.1	21
189	Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. Breast Cancer Research, 2017, 19, 76.	5.0	59
190	Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget, 2017, 8, 113105-113119.	1.8	2
191	Combining vasculature disrupting agent and toll-like receptor 7/8 agonist for cancer therapy. Oncotarget, 2017, 8, 5371-5381.	1.8	28
192	Cancer Immunotherapy. , 2017, , 32-65.		1
193	The Role of Activating and Inhibitory NK Cell Receptors in Antitumor Immune Response. , 0, , .		8
194	NK Cells in Cancer Immunotherapy. , 0, , .		0
195	Tumor location impacts immune response in mouse models of colon cancer. Oncotarget, 2017, 8, 54775-54787.	1.8	75
196	Natural killer cells in liver diseases. Frontiers of Medicine, 2018, 12, 269-279.	3.4	19
197	Solubility-enhanced gMYL6 fused with a hexa-lysine tag promotes the cytotoxicity of human NK cells. Immunology Letters, 2018, 198, 66-73.	2.5	3
198	Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment. Journal of Immunotherapy, 2018, 41, 261-273.	2.4	12

#	Article	IF	CITATIONS
199	<scp>MRI</scp> â€guided interventional natural killer cell delivery for liver tumor treatment. Cancer Medicine, 2018, 7, 1860-1869.	2.8	23
200	Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 200-215.	7.4	32
201	Immunological Aspects of Cryoablation of Non–Small Cell Lung Cancer: A Comprehensive Review. Journal of Thoracic Oncology, 2018, 13, 624-635.	1.1	35
202	In vitro -induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells. Experimental Cell Research, 2018, 364, 113-123.	2.6	20
203	Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression. Oncolmmunology, 2018, 7, e1395123.	4.6	37
204	Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion. Stem Cells, 2018, 36, 641-654.	3.2	42
206	Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function. Clinical Cancer Research, 2018, 24, 1891-1904.	7.0	172
207	Modulation the expression of natural killer cell activating receptor (NKp44) in the peripheral blood of diffuse large B-cell lymphoma patients and the correlation with clinic pathological features. Clinical Immunology, 2018, 188, 38-44.	3.2	2
208	Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?. Journal of Medicinal Chemistry, 2018, 61, 5073-5092.	6.4	79
209	Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunology, Immunotherapy, 2018, 67, 575-587.	4.2	36
211	Circulating Tumor Cells: Diagnostic and Therapeutic Applications. Annual Review of Biomedical Engineering, 2018, 20, 329-352.	12.3	79
212	Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacologica Sinica, 2018, 39, 167-176.	6.1	121
213	Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. Journal of Immunotherapy, 2018, 41, 64-72.	2.4	29
214	Cancer immunotherapy μ-environment LabChip: taking advantage of optoelectronic tweezers. Lab on A Chip, 2018, 18, 106-114.	6.0	34
215	Anticancer cellular immunotherapies derived from umbilical cord blood. Expert Opinion on Biological Therapy, 2018, 18, 121-134.	3.1	18
216	Tumor immunotherapy: New aspects of natural killer cells. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 173-196.	2.2	52
218	Highlighting the Role of DC-NK Cell Interplay in Immunobiology and Immunotherapy. , 2018, , .		7
219	Natural Killer Cells: Prospects in Cancer Immunotherapy. Current Immunology Reviews, 2018, 14, 100-104.	1.2	0

#	Article	IF	CITATIONS
220	Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. Journal of Experimental and Clinical Cancer Research, 2018, 37, 297.	8.6	11
221	Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report. OncoTargets and Therapy, 2018, Volume 11, 7345-7352.	2.0	11
222	Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression. Frontiers in Immunology, 2018, 9, 1990.	4.8	29
223	Cell Culture Technology. Learning Materials in Biosciences, 2018, , .	0.4	6
224	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treatment Reviews, 2018, 70, 232-244.	7.7	36
225	Cell Culture Bioprocess Technology: Biologics and Beyond. Learning Materials in Biosciences, 2018, , 1-21.	0.4	1
226	The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia. Blood Research, 2018, 53, 198.	1.3	7
227	Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell International, 2018, 18, 133.	4.1	28
228	Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy. OncoTargets and Therapy, 2018, Volume 11, 5763-5775.	2.0	37
229	An overview of cancer immunotherapeutic strategies. Immunotherapy, 2018, 10, 999-1010.	2.0	26
230	Elevated levels of the small GTPase Cdc42 induces senescence in male rat mesenchymal stem cells. Biogerontology, 2018, 19, 287-301.	3.9	22
231	Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer. Oncology Letters, 2018, 15, 7014-7020.	1.8	11
232	Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell, 2018, 23, 181-192.e5.	11.1	634
233	<i>In Vivo</i> Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model. In Vivo, 2018, 32, 771-781.	1.3	54
235	Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells. BMC Immunology, 2018, 19, 27.	2.2	26
236	Challenges of NK cell-based immunotherapy in the new era. Frontiers of Medicine, 2018, 12, 440-450.	3.4	34
237	Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 1409.	4.8	55
238	hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1279-1288.	2.5	9

	Сітат	tion Report	
#	Article	IF	CITATIONS
239	Magnetic delivery of Fe <sub>3</sub> O <sub>4</sub> @polydopamine nanoparticle-loaded natural killer cells suggest a promising anticancer treatment. Biomaterials Science, 2018, 6, 2714-2725.	5.4	86
240	Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome. Cellular Physiology and Biochemistry, 2018, 48, 1882-1893.	1.6	45
241	Molecular Basis of Lymphoid and Myeloid Diseases. , 2018, , 299-328.		2
242	Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells. Journal of Cellular Physiology, 2019, 234, 259-273.	4.1	43
243	Preservation of cell-based immunotherapies for clinical trials. Cytotherapy, 2019, 21, 943-957.	0.7	70
244	State of the Art of Natural Killer Cell Imaging: A Systematic Review. Cancers, 2019, 11, 967.	3.7	12
245	Expression of carcinoma, apoptosis, and cellâ€death–related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatric Blood and Cancer, 2019, 66, e27783.	1.5	11
246	Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Scientific Reports, 2019, 9, 14916.	3.3	66
247	Recovery and functionality of cryopreserved peripheral blood mononuclear cells using five different xeno-free cryoprotective solutions. Cryobiology, 2019, 86, 25-32.	0.7	9
248	IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. BMC Cancer, 2019, 19, 1053.	2.6	37
249	Progranulin promotes melanoma progression by inhibiting natural killer cell recruitment to the tumor microenvironment. Cancer Letters, 2019, 465, 24-35.	7.2	18
250	Natural killer cells and cancer therapy, what we know and where we are going. Immunotherapy, 2019, 11, 1231-1251.	2.0	8
251	Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ. Frontiers in Pharmacology, 2019, 10, 898.	3.5	17
252	The Immune Microenvironment of Breast Cancer Progression. Cancers, 2019, 11, 1375.	3.7	68
253	Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Communications, 2019, 39, 1-16.	9.2	49
254	CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse. Scientific Reports, 2019, 9, 8756.	3.3	23
255	Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy. Cancers, 2019, 11, 769.	3.7	138
256	Immunostimulating and Antimetastatic Effects of Polysaccharides Purified from Ginseng Berry. The American Journal of Chinese Medicine, 2019, 47, 823-839.	3.8	28

#	Article	IF	CITATIONS
257	Molecular and immune targets for Merkel cell carcinoma therapy and prevention. Molecular Carcinogenesis, 2019, 58, 1602-1611.	2.7	5
258	Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors. Frontiers in Pharmacology, 2019, 10, 326.	3.5	17
259	Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Frontiers in Immunology, 2019, 10, 1205.	4.8	292
260	Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56 <sup>Dim</sup> NK cells. Innate Immunity, 2019, 25, 294-304.	2.4	8
261	Roles of exosomes in liver metastases: Novel diagnosis and treatment choices. Journal of Cellular Physiology, 2019, 234, 21588-21600.	4.1	13
262	CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway. Journal of Immunology Research, 2019, 2019, 1-15.	2.2	13
263	NK cells: An attractive candidate for cancer therapy. Journal of Cellular Physiology, 2019, 234, 19352-19365.	4.1	55
264	Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro. PLoS ONE, 2019, 14, e0212455.	2.5	31
265	Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects. Engineering, 2019, 5, 106-114.	6.7	30
266	Rhamnogalacturonan-I-Type Polysaccharide Purified from Broccoli Exerts Anti-Metastatic Activities Via Innate Immune Cell Activation. Journal of Medicinal Food, 2019, 22, 451-459.	1.5	9
267	Flipâ€flops of natural killer cells in autoimmune diseases versus cancers: Immunologic axis. Journal of Cellular Physiology, 2019, 234, 16998-17010.	4.1	7
268	Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function. BMC Immunology, 2019, 20, 8.	2.2	40
269	Plant Virus-Like Particle In Situ Vaccine for Intracranial Glioma Immunotherapy. Cancers, 2019, 11, 515.	3.7	55
270	Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody. Veterinary Immunology and Immunopathology, 2019, 211, 10-18.	1.2	14
271	Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects. Cancers, 2019, 11, 461.	3.7	119
272	Ethical considerations of cellular immunotherapy for cancer. Journal of Zhejiang University: Science B, 2019, 20, 23-31.	2.8	5
273	CRTAM+ NK cells endowed with suppressor properties arise in leukemic bone marrow. Journal of Leukocyte Biology, 2019, 105, 999-1013.	3.3	12
274	Therapeutic Potential of Natural Killer Cells in Gastric Cancer. Frontiers in Immunology, 2018, 9, 3095.	4.8	43

		CITATION REPORT		
#	Article		IF	CITATIONS
275	Immunometabolism and natural killer cell responses. Nature Reviews Immunology, 2019,	19, 282-290.	22.7	254
276	Memory and CARâ€NK cellâ€based novel approaches for HIV vaccination and eradication. Cellular Physiology, 2019, 234, 14812-14817.	. Journal of	4.1	11
277	Re-evaluation of the linear no-threshold (LNT) model using new paradigms and modern m studies. Chemico-Biological Interactions, 2019, 301, 54-67.	olecular	4.0	45
278	Laminarin enhances the activity of natural killer cells in immunosuppressed mice. Central- Journal of Immunology, 2019, 44, 357-363.	European	1.2	8
279	Mobilization and collection of cells in the hematologic compartment for cellular therapies cell collection with G-CSF/plerixafor, collecting lymphocytes/monocytes. Seminars in Hem 2019, 56, 248-256.	:: Stem atology,	3.4	7
280	Activation of natural killer cells by rituximab in granulomatosis with polyangiitis. Arthritis and Therapy, 2019, 21, 277.	Research	3.5	7
281	<i>Ganoderma lucidum</i> Polysaccharide Enhanced the Antitumor Effects of 5-Fluoroura Gastric Cancer through Its Upregulation of NKG2D/MICA. International Journal of Polymer 2019, 2019, 1-7.	acil against <sup>·</sup> Science,	2.7	6
282	Natural Killer Cells in Cancer Immunotherapy. Annual Review of Cancer Biology, 2019, 3, 3	77-103.	4.5	122
283	Natural killer cell–mediated anticancer effects of an arabinogalactan derived from rice h colon cancer–bearing mice. International Journal of Biological Macromolecules, 2019, 1	null in CT26 .24, 368-376.	7.5	10
284	Cell transferâ€based immunotherapies in cancer: A review. IUBMB Life, 2020, 72, 790-800	D.	3.4	12
285	Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. Nanoscale, 2020, 12, 413-436.		5.6	49
286	Beyond CAR-T cells: Natural killer cells immunotherapy. Medicina ClÃnica (English Edition) 134-141.	), 2020, 154,	0.2	1
287	Immunological role and underlying mechanisms of B7â€H6 in tumorigenesis. Clinica Chin 502, 191-198.	nica Acta, 2020,	1.1	17
288	Role of the Cyclooxygenase Pathway in the Association of Obstructive Sleep Apnea and C Journal of Clinical Medicine, 2020, 9, 3237.	ancer.	2.4	5
289	NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent adva trends. Seminars in Immunology, 2020, 48, 101407.	nces and	5.6	31
290	Expansion and Activation of Human Natural Killer Cells ex vivo in the Presence of Transger Cells. Cell and Tissue Biology, 2020, 14, 365-371.	nic Feeder	0.4	2
291	Effect of interleukins (IL-2, IL-15, IL-18) on receptors activation and cytotoxic activity of no cells in breast cancer cell. African Health Sciences, 2020, 20, 822-832.	atural killer	0.7	25
292	Clinical implication of cellular vaccine in glioma: current advances and future prospects. Jo Experimental and Clinical Cancer Research, 2020, 39, 257.	purnal of	8.6	31

#	Article	IF	CITATIONS
293	Inflammatory Cells in Diffuse Large B Cell Lymphoma. Journal of Clinical Medicine, 2020, 9, 2418.	2.4	29
294	Natural Born Killers: NK Cells in Cancer Therapy. Cancers, 2020, 12, 2131.	3.7	44
295	Understanding the Role of Innate Immune Cells and Identifying Genes in Breast Cancer Microenvironment. Cancers, 2020, 12, 2226.	3.7	21
296	Conditional Deletion of PGC-1α Results in Energetic and Functional Defects in NK Cells. IScience, 2020, 23, 101454.	4.1	11
297	<scp>NK</scp> cell alloreactivity in acute myeloid leukemia in the postâ€ŧransplant cyclophosphamide era. American Journal of Hematology, 2020, 95, 1590-1598.	4.1	7
298	Natural-Killer-Cell-Inspired Nanorobots with Aggregation-Induced Emission Characteristics for Near-Infrared-II Fluorescence-Guided Glioma Theranostics. ACS Nano, 2020, 14, 11452-11462.	14.6	156
299	Natural killer cell-based immunotherapy for acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 167.	17.0	55
300	Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 168.	17.0	114
301	Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. Frontiers in Immunology, 2020, 11, 575609.	4.8	34
302	TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy. Molecular Pharmaceutics, 2020, 17, 2109-2124.	4.6	28
303	Deciphering Natural Killer Cell Homeostasis. Frontiers in Immunology, 2020, 11, 812.	4.8	34
304	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. Cancers, 2020, 12, 1153.	3.7	4
305	CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. Journal of Hematology and Oncology, 2020, 13, 76.	17.0	65
306	MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nature Communications, 2020, 11, 2860.	12.8	45
307	Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer. Frontiers in Immunology, 2020, 11, 331.	4.8	41
308	Targeting Natural Killer Cells for Tumor Immunotherapy. Frontiers in Immunology, 2020, 11, 60.	4.8	80
309	Human Mesenchymal Stem Cells Overexpressing Interleukin 2 Can Suppress Proliferation of Neuroblastoma Cells in Co-Culture and Activate Mononuclear Cells In Vitro. Bioengineering, 2020, 7, 59.	3.5	26
310	Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. Cells, 2020, 9, 1578.	4.1	8

ARTICLE IF CITATIONS The future of cryoablation: An abscopal effect. Cryobiology, 2020, 97, 1-4. 311 0.7 10 Harnessing Natural Killer Cells' Killing Function in Cancer. , 2020, , 91-155. Seleniumâ€Containing Nanoparticles Combine the NK Cells Mediated Immunotherapy with Radiotherapy 313 21.0 192 and Chemotherapy. Advanced Materials, 2020, 32, e1907568. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 190-198. 314 Mechanism of tumor cells escaping from immune surveillance of NK cells. Immunopharmacology and 315 2.4 17 Immunotoxicology, 2020, 42, 187-198. Association of CD200 expression in paternal lymphocytes with female Th1/Th2 balance and pregnancy establishment at immunotherapy of recurrent spontaneous abortion. American Journal of Reproductive Immunology, 2021, 85, e13355. 1.2 NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming 317 1.2 16 Limitations. Transplantation and Cellular Therapy, 2021, 27, 21-35. Progress in research into the role of abnormal glycosylation modification in tumor immunity. 318 2.5 Immunology Letters, 2021, 229, 8-17. Angel or Devil ? - CDK8 as the new drug target. European Journal of Medicinal Chemistry, 2021, 213, 319 5.5 15 113043. Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion. International Reviews 3.3 of Immunology, 2021, 40, 197-216. Preparation and characterization of folic acid conjugated sulfated polysaccharides on NK cell 321 10.2 11 activation and cellular uptake in HeLa cells. Carbohydrate Polymers, 2021, 254, 117250. Current progress in cancer immunotherapy based on natural killer cells. Cell Biology International, 3.0 2021, 45, 2-17. Synthetic Antibody Mimics Based on Cancerâ€Targeting Immunostimulatory Peptides. ChemBioChem, 2021, 323 2.6 2 22, 1589-1596. Allogeneic VÎ<sup>3</sup>9VÎ<sup>2</sup> T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of 324 patients with late-stage lung or liver cancer. Cellular and Molecular Immunology, 2021, 18, 427-439. The effectiveness and safety of lienal polypeptide combined with chemotherapy or chemoradiotherapy 325 1.0 1 for non-small cell lung cancer patients in real world. Medicine (United States), 2021, 100, e24272. Non-invasive and label-free identification of human natural killer cell subclasses by biophysical single-cell features in microfluidic flow. Lab on A Chip, 2021, 21, 4144-4154. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen 327 2.4 7 receptors. BMB Reports, 2021, 54, 44-58. Next-Generation Immunotherapies to Improve Anticancer Immunity. Frontiers in Pharmacology, 2020, 328 11, 566401.

#	Article	IF	CITATIONS
329	NK cell-mediated immunotherapy: The exquisite role of PGC-1a in metabolic reprogramming. , 2021, , 121-142.		0
330	Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β. , 2021, 9, e001740.		18
331	Clinical development of natural killer cells expressing chimeric antigen receptors. Transfusion and Apheresis Science, 2021, 60, 103065.	1.0	0
332	Computational screening of potential glioma-related genes and drugs based on analysis of GEO dataset and text mining. PLoS ONE, 2021, 16, e0247612.	2.5	4
333	Natural Killer Cells: Potential Biomarkers and Therapeutic Target in Autoimmune Diseases?. Frontiers in Immunology, 2021, 12, 616853.	4.8	36
334	The Advances and Challenges of NK Cell-Based Cancer Immunotherapy. Current Oncology, 2021, 28, 1077-1093.	2.2	24
335	Cell therapies in the clinic. Bioengineering and Translational Medicine, 2021, 6, e10214.	7.1	68
336	iMAP: integration of multiple single-cell datasets by adversarial paired transfer networks. Genome Biology, 2021, 22, 63.	8.8	26
337	IL-10 Enhances Human Natural Killer Cell Effector Functions via Metabolic Reprogramming Regulated by mTORC1 Signaling. Frontiers in Immunology, 2021, 12, 619195.	4.8	29
338	Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Research and Therapy, 2021, 12, 200.	5.5	25
339	Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective. Cells, 2021, 10, 543.	4.1	14
340	Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells. Current Cancer Drug Targets, 2021, 21, 117-131.	1.6	4
341	NKâ€Cell Biofactory as an Offâ€theâ€Shelf Cellâ€based Vector for Targeted In Situ Synthesis of Engineered Proteins. Advanced Biology, 2021, 5, e2000298.	2.5	6
342	Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies. Cancers, 2021, 13, 1988.	3.7	14
343	Advances in immunotherapy for COVID-19: A comprehensive review. International Immunopharmacology, 2021, 93, 107409.	3.8	16
344	Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines. Life Sciences, 2021, 271, 119110.	4.3	25
345	Development and validation of an immunoassay for quantification of NCAM-1 in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2021, 197, 113981.	2.8	2
346	Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy. Expert Review of Clinical Immunology, 2021, 17, 643-659.	3.0	5

#	Article	IF	CITATIONS
347	Overview of Cellular Immunotherapies within Transfusion Medicine for the Treatment of Malignant Diseases. International Journal of Molecular Sciences, 2021, 22, 5120.	4.1	0
348	A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers. Frontiers in Oncology, 2021, 11, 649710.	2.8	16
349	Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. Cancer Letters, 2021, 507, 55-69.	7.2	53
350	Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. Translational Lung Cancer Research, 2021, 10, 2788-2805.	2.8	3
351	Development of Precision Medical Technology and its Current Clinical Applications. Recent Patents on Engineering, 2021, 15, .	0.4	0
352	Magneto-Activation and Magnetic Resonance Imaging of Natural Killer Cells Labeled with Magnetic Nanocomplexes for the Treatment of Solid Tumors. ACS Nano, 2021, 15, 12780-12793.	14.6	36
353	The potential of cord blood to replenish young immune cells against cancer. Aging and Cancer, 2021, 2, 36-44.	1.6	0
354	Telomerase Reverse Transcriptase Increases Proliferation and Lifespan of Human NK Cells without Immortalization. Biomedicines, 2021, 9, 662.	3.2	9
355	CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Research and Therapy, 2021, 12, 374.	5.5	33
356	Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia. Journal of Personalized Medicine, 2021, 11, 697.	2.5	6
357	Modulating Repolarization of Tumor-Associated Macrophages with Targeted Therapeutic Nanoparticles as a Potential Strategy for Cancer Therapy. ACS Applied Bio Materials, 2021, 4, 5871-5896.	4.6	8
358	Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy. International Immunopharmacology, 2021, 96, 107714.	3.8	6
359	Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements. Biomolecules, 2021, 11, 1066.	4.0	2
360	Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 1089-1089.	1.7	5
361	Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment. ACS Nano, 2021, 15, 12567-12603.	14.6	112
362	Chimeric antigen receptor T-cell therapy for breast cancer. Future Oncology, 2021, 17, 2961-2979.	2.4	0
363	Specific Blood Cells Derived from Pluripotent Stem Cells: An Emerging Field with Great Potential in Clinical Cell Therapy. Stem Cells International, 2021, 2021, 1-16.	2.5	1
364	Methionine enkephalin (MENK) suppresses lung cancer by regulating the Bcl-2/Bax/caspase-3 signaling pathway and enhancing natural killer cell-driven tumor immunity. International Immunopharmacology, 2021, 98, 107837.	3.8	22

#	Article	IF	CITATIONS
365	Repurposing macitentan with nanoparticle modulates tumor microenvironment to potentiate immune checkpoint blockade. Biomaterials, 2021, 276, 121058.	11.4	13
366	Natural killer cellâ€ʿbased immunotherapy for lung cancer: Challenges and perspectives (Review). Oncology Reports, 2021, 46, .	2.6	14
367	Recent advances in regenerative medicine strategies for cancer treatment. Biomedicine and Pharmacotherapy, 2021, 141, 111875.	5.6	38
368	Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors. International Journal of Molecular Sciences, 2021, 22, 9975.	4.1	10
369	Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects. Stem Cell Reviews and Reports, 2021, 17, 2081-2106.	3.8	38
370	Biomaterials and devices for immunotherapy. , 2022, , 97-133.		Ο
371	CAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product. , 2021, , 213-230.		2
372	Allâ€ŧrans retinoic acid induces leukemia resistance to NK cell cytotoxicity by downâ€regulating B7â€H6 expression via câ€Myc signaling. Cancer Communications, 2021, 41, 51-61.	9.2	2
373	New therapeutic modalities in breast cancer by targeting NK cell inhibitory and activating receptors. , 2021, , 387-402.		0
374	Landscape and Dynamics of the Transcriptional Regulatory Network During Natural Killer Cell Differentiation. Genomics, Proteomics and Bioinformatics, 2020, 18, 501-515.	6.9	16
375	Más allá de las células CAR-T, inmunoterapia con linfocitos natural killer. Medicina ClÃnica, 2020, 154, 134-141.	0.6	3
376	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. Urologic Clinics of North America, 2020, 47, e17-e54.	1.8	39
377	Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis. Nature Communications, 2019, 10, 574.	12.8	93
380	Metabolic regulation of immune responses: therapeutic opportunities. Journal of Clinical Investigation, 2016, 126, 2031-2039.	8.2	78
381	Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS ONE, 2018, 13, e0191358.	2.5	93
382	High Intensity Interval Training Increases Natural Killer Cell Number and Function in Obese Breast Cancer-challenged Mice and Obese Women. Journal of Cancer Prevention, 2017, 22, 260-266.	2.0	29
383	LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES. Medical Immunology (Russia), 2015, 16, 567.	0.4	1
384	SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice. Oncotarget, 2016, 7, 49509-49526.	1.8	17

#	Article	IF	CITATIONS
385	A long noncoding RNA positively regulates CD56 in human natural killer cells. Oncotarget, 2016, 7, 72546-72558.	1.8	39
386	Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. Oncotarget, 2017, 8, 81967-81977.	1.8	43
387	Programmed differentiated natural killer cells kill leukemia cells by engaging SLAM family receptors. Oncotarget, 2017, 8, 57024-57038.	1.8	6
388	Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway. Oncotarget, 2017, 8, 80506-80520.	1.8	59
389	Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway. Oncotarget, 2017, 8, 65743-65758.	1.8	52
390	An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. Oncotarget, 2017, 8, 101795-101807.	1.8	31
391	Epigenetic changes found in uterine decidual and placental tissues can also be found in the breast cancer microenvironment of the same unique patient: description and potential interpretations. Oncotarget, 2018, 9, 6028-6041.	1.8	8
392	Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients. Oncotarget, 2018, 9, 27171-27196.	1.8	7
393	Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience. Oncotarget, 2019, 10, 6138-6151.	1.8	3
394	Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells. Oncotarget, 2016, 7, 7318-7328.	1.8	15
395	Natural Killer Cell Diversity in Viral Infection: Why and How Much?. Pathogens and Immunity, 2016, 1, 165.	3.1	25
396	Natural killer cels in immunotherapy for cancer. Siberian Journal of Oncology, 2019, 17, 97-104.	0.3	3
397	The Antitumor Immunity Mediated by NK Cells: The Role of The NCRs. The Open Cancer Immunology Journal, 2018, 07, 7-15.	0.2	1
398	Natural Killer Cell Viability After Hyperthermia Alone or Combined with Radiotherapy with or without Cytokines. Anticancer Research, 2018, 38, 655-663.	1.1	3
399	Decreased IL-1ra and NCAM-1/CD56 Serum Levels in Unmedicated Patients with Schizophrenia Before and After Antipsychotic Treatment. Psychiatry Investigation, 2018, 15, 727-732.	1.6	5
400	Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3797-3803.	1.2	8
401	NK Cell-Based Immunotherapies in Cancer. Immune Network, 2020, 20, e14.	3.6	79
402	Safety of Lienal Polypeptide Injection Combined with Chemotherapy in Treating Patients with Advanced Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7837-7841.	1.2	9

#	Article	IF	CITATIONS
403	Natural Killer Cells - Their Role in Tumour Immunosurveillance. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, BE01-BE05.	0.8	25
404	When and How to Evaluate the Natural Killer Cell Function. Annual Research & Review in Biology, 2014, 4, 3586-3614.	0.4	2
405	Activation of Cascadeâ€Like Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT. Advanced Healthcare Materials, 2022, 11, e2102080.	7.6	5
406	The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. International Immunopharmacology, 2021, 101, 108220.	3.8	6
407	CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells and T Cells Enhance In Vitro and In Vivo Anti-Tumor Activity Against Human Multiple Myeloma. Blood, 2013, 122, 14-14.	1.4	2
408	An Overview of Treatment for Cervical Cancer with Emphasis on Immune Cell-Based Therapies. , 2015, , 933-953.		0
409	Natural Killer Cells: A Potential Therapy for Paediatric Brain Tumours. Journal of Carcinogenesis & Mutagenesis, 2015, 06, .	0.3	0
410	Tumor Induces the Expansion of Foxp3+CD25high and CD11b+Gr-1+ Cell Population in the Early Phase of Tumor Progression. Biomedical Science Letters, 2015, 21, 172-180.	0.3	2
411	Clinical Applications of Induced Pluripotent Stem Cells in Cancer. Pancreatic Islet Biology, 2016, , 131-158.	0.3	0
412	Natural killer cell: An immuno-oncology novel target for cancer therapy?. Journal of Oral and Maxillofacial Pathology, 2017, 21, 332.	0.6	0
414	Autotransplantation of T-lymphocytes as a tool for antigen-specific immunotherapy of oncological diseases. Vestnik Transplantologii I Iskusstvennykh Organov, 2018, 20, 95-104.	0.4	2
416	Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies. ImmunoTargets and Therapy, 2021, Volume 10, 387-407.	5.8	9
417	The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. ChemistrySelect, 2022, 7, 833-866.	1.5	0
419	Induced pluripotent stem cells in dentistry. Journal of Pharmacy and Bioallied Sciences, 2016, 8, S23-S27.	0.6	2
420	Immunohistochemical Expression of CD and ALDH in Common Salivary Gland Tumors. Iranian Journal of Otorhinolaryngology, 2016, 28, 389-397.	0.4	2
421	Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells. Enliven Journal of Stem Cell Research & Regenerative Medicine, 2016, 3, .	0.2	0
422	Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC). American Journal of Cancer Research, 2018, 8, 879-891.	1.4	7
424	Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 337-349.	1.4	0

#	Article	IF	CITATIONS
425	The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy. Vaccines, 2021, 9, 1363.	4.4	20
426	Advances in NK cell production. Cellular and Molecular Immunology, 2022, 19, 460-481.	10.5	20
427	The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach. Pharmacological Reports, 2022, 74, 379-391.	3.3	1
428	NK Hücre Aktivitesinde İmmunomodulatör Etki Gösteren Moleküller. Black Sea Journal of Health Science, 0, , .	0.9	0
429	The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cellular and Molecular Immunology, 2022, 19, 192-209.	10.5	51
430	Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article. International Immunopharmacology, 2022, 105, 108580.	3.8	5
431	Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18. Cancer Immunology, Immunotherapy, 2022, 71, 2227-2238.	4.2	23
432	The tumor immune-microenvironment in gastric cancer. Tumori, 2022, 108, 541-551.	1.1	12
433	Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood, 2022, 139, 1670-1683.	1.4	57
434	Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. Gynecologic Oncology, 2022, 165, 664-670.	1.4	7
435	CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Frontiers in Oncology, 2022, 12, 834002.	2.8	8
436	Tumor microenvironment in salivary gland carcinomas: An orchestrated state of chaos. Oral Oncology, 2022, 127, 105777.	1.5	5
437	Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions In Vitro and In Vivo. Frontiers in Immunology, 2022, 13, 861681.	4.8	11
438	Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia. Frontiers in Immunology, 2021, 12, 737340.	4.8	12
439	Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD‣1. Advanced Science, 2022, 9, e2103245.	11.2	22
440	CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response. Current Gene Therapy, 2021, 22, .	2.0	11
441	Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer. Journal of Interferon and Cytokine Research, 2021, 41, 450-460.	1.2	12
442	The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review. Biomarkers, 2022, 27, 22-34.	1.9	1

#	Article	IF	CITATIONS
443	Sialic acids: An Avenue to Target Cancer Progression, Metastasis, and Resistance to Therapy. Forum of Clinical Oncology, 2021, 12, 40-48.	0.2	2
444	The tricks for fighting against cancer using CAR NK cells: A review. Molecular and Cellular Probes, 2022, 63, 101817.	2.1	5
456	Induced pluripotent stem cells in dentistry. Journal of Pharmacy and Bioallied Sciences, 2016, 8, 23.	0.6	9
457	Immune Infiltration Characteristics and a Gene Prognostic Signature Associated With the Immune Infiltration in Head and Neck Squamous Cell Carcinoma. Frontiers in Genetics, 2022, 13, 848841.	2.3	5
458	Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy. International Immunopharmacology, 2022, 109, 108783.	3.8	8
459	Reduced Expression of Natural Killer Cell-Related Activating Receptors by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer and Their Improvement by Zoledronic Acid. Asian Pacific Journal of Cancer Prevention, 2022, 23, 1661-1669.	1.2	1
460	Natural killer cells: a promising immunotherapy for cancer. Journal of Translational Medicine, 2022, 20, .	4.4	56
461	A general toxicity and biodistribution study of human natural killer cells by single or repeated intravenous dose in severe combined immune deficient mice. Toxicological Research, 2022, 38, 545-555.	2.1	0
462	Nanobiomaterials to modulate natural killer cell responses for effective cancer immunotherapy. Trends in Biotechnology, 2023, 41, 77-92.	9.3	7
463	iPSCs in NK Cell Manufacturing and NKEV Development. Frontiers in Immunology, 0, 13, .	4.8	7
464	An Imaging Flow Cytometry Method for Assessment of Human Natural Killer Cells. Bio-Medical Engineering, 0, , .	0.5	0
465	The role of the natural killer (NK) cell modulation in breast cancer incidence and progress. Molecular Biology Reports, 2022, 49, 10935-10948.	2.3	6
466	Kinetic, imaging based assay to measure NK cell cytotoxicity against adherent cells. Methods in Cell Biology, 2023, , 63-91.	1.1	2
467	Current Trends in Immuno-Oncology. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2023, 21, 96-107.	1.0	1
468	KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nature Medicine, 2022, 28, 2133-2144.	30.7	50
469	Studying the Anticancer Effects of Thymoquinone on Breast Cancer Cells through Natural Killer Cell Activity. BioMed Research International, 2022, 2022, 1-8.	1.9	0
470	Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach. Vaccines, 2022, 10, 1493.	4.4	5
471	Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment. Breast Cancer Research, 2022, 24, .	5.0	6

~			~	
		ON	REDC	DT
$\sim$	плп		NLFC	ואכ

#	Article	IF	CITATIONS
472	Natural Killer Cells Are Key Host Immune Effector Cells Affecting Survival in Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation. Cells, 2022, 11, 3469.	4.1	1
473	A combination of telomerase inhibition and NK cell therapy increased breast cancer cell line apoptosis. Biochemical and Biophysical Research Communications, 2023, 640, 50-55.	2.1	6
475	Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours. Clinical Oncology, 2023, 35, 153-162.	1.4	2
476	Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper. Frontiers in Oncology, 0, 12, .	2.8	0
477	Chasing Uterine Cancer with NK Cell-Based Immunotherapies. Future Pharmacology, 2022, 2, 642-659.	1.8	3
478	GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis. Molecular Pharmaceutics, 2023, 20, 971-986.	4.6	7
479	Long non-coding RNAs: The modulators of innate and adaptive immune cells. Pathology Research and Practice, 2023, 241, 154295.	2.3	1
482	Lactate-related metabolic reprogramming and immune regulation in colorectal cancer. Frontiers in Endocrinology, 0, 13, .	3.5	1
483	Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy. Frontiers in Immunology, 0, 13, .	4.8	4
484	TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer. Turkish Journal of Haematology, 2023, 40, 1-10.	0.5	2
486	PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion. Clinical and Translational Oncology, 2023, 25, 2373-2383.	2.4	3
487	Immune Gene Therapy of Cancer. , 2023, , 1-45.		0
488	Nanomedicine for Tâ $\in$ Cell Mediated Immunotherapy. Advanced Materials, 0, , .	21.0	6
489	The immunomodulatory mechanisms for acupuncture practice. Frontiers in Immunology, 0, 14, .	4.8	8
490	Antitumor effects of NK cells expanded by activation pre‑processing of autologous feeder cells before irradiation in colorectal cancer. Oncology Letters, 2023, 25, .	1.8	0
491	Molecular imaging of innate immunity and immunotherapy. Advanced Drug Delivery Reviews, 2023, 198, 114865.	13.7	3
492	Advances in natural killer cell therapies for breast cancer. Immunology and Cell Biology, 2023, 101, 705-726.	2.3	3
493	Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy. Biomedicines, 2023, 11, 1768.	3.2	1

#	Article	IF	CITATIONS
494	NK cells encapsulated in micro/macropore-forming hydrogels via 3D bioprinting for tumor immunotherapy. Biomaterials Research, 2023, 27, .	6.9	8
495	Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome. Biomedicine and Pharmacotherapy, 2023, 165, 115104.	5.6	7
496	Natural killer cell therapy targeting cancer stem cells: Old wine in a new bottle. Cancer Letters, 2023, 570, 216328.	7.2	3
497	NK cell-based tumor immunotherapy. Bioactive Materials, 2024, 31, 63-86.	15.6	0
498	Mediastinal lymph node removal modulates natural killer cell exhaustion in patients with non-small cell lung cancer. Immunologic Research, 0, , .	2.9	1
499	Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma. Nature Cancer, 2023, 4, 1437-1454.	13.2	3
500	Oridonin enhances cytotoxic activity of natural killer cells against lung cancer. International Immunopharmacology, 2023, 122, 110669.	3.8	4
501	Breast cancer immunotherapy: a comprehensive review. Clinical and Experimental Medicine, 2023, 23, 4431-4447.	3.6	1
502	Deciphering the immune reaction leading to spontaneous melanoma regression: initial role of MHCII+ CD163â´´ macrophages. Cancer Immunology, Immunotherapy, 2023, 72, 3507-3521.	4.2	1
503	Application of cell-derived exosomes in the hematological malignancies therapy. Frontiers in Pharmacology, 0, 14, .	3.5	1
504	Efficacy of gilteritinib in comparison with alectinib for the treatment of <i>ALK</i> â€rearranged nonâ€small cell lung cancer. Cancer Science, 0, , .	3.9	0
505	The effect of mitochondria inhibition on natural killer cells cytotoxicity in triple-negative breast cancer cells. European Journal of Pharmacology, 2023, 960, 176106.	3.5	0
506	Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	1
507	Direct tumor irradiation potentiates adoptive NK cell targeting against parental and stem-like cancer in human liver cancer models International Journal of Radiation Oncology Biology Physics, 2023, , .	0.8	0
508	A clinically relevant largeâ€scale biomanufacturing workflow to produce natural killer cells and natural killer cellâ€derived extracellular vesicles for cancer immunotherapy. Journal of Extracellular Vesicles, 2023, 12, .	12.2	0
510	Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review. Biomedicines, 2024, 12, 183.	3.2	0
511	Tumor microenvironment and immune system preservation in early-stage breast cancer: routes for early recurrence after mastectomy and treatment for lobular and ductal forms of disease. BMC Immunology, 2024, 25, .	2.2	0
512	Pterostilbene upregulates MICA/B via the PI3K/AKT signaling pathway to enhance the capability of natural killer cells to kill cervical cancer cells. Experimental Cell Research, 2024, 435, 113933.	2.6	2

#	Article	IF	CITATIONS
513	Targeting NKG2D/NKG2DL axis in multiple myeloma therapy. Cytokine and Growth Factor Reviews, 2024, 76, 1-11.	7.2	0
514	Induced Pluripotent Stem Cells – A New Perspective toward Regenerative Dentistry and Prosthodontics: A Narrative Review Article. Journal of Dental Research and Review, 2023, 10, 221-227.	0.1	0
515	A novel type-2 innate lymphoid cell-based immunotherapy for cancer. Frontiers in Immunology, 0, 15, .	4.8	0
517	Suspension culture promoted the expansion of NKâ $\in$ 92 cells ex vivo by enhancing the expression of ILâ $\in$ 2 receptor. Biotechnology Journal, 2024, 19, .	3.5	0
518	Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications. Cancer Cell International, 2024, 24, .	4.1	0